William Borden

Big pharma’s finicky appetite for M&A comes as valuations of sellers soften. Though the pace of deals has picked up some, predicting just how long both sides will hold tight remains difficult.

Curative-type therapies offer great hope in further transforming treatments for cancer and other diseases, but addressing the economics of these products—and ultimately the cost-benefit equation—is daunting. What is being done to smooth the path for pricing and reimbursement?

Pharma and legal experts weigh in on the rush to secure intellectual property around psychedelic medicines, the value imperative that should govern pricing strategies, and the likely long-haul battle for more widespread decriminalization of these drugs.